— ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial —
Reno, Nevada (UroToday.com) — UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).